bioAffinity Technologies Reports Continued Sales Growth For Its Noninvasive Lung Cancer Test, CyPath Lung, With Test Volumes More Than Doubling Since The Start Of 2025

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced continued sales growth of its noninvasive lung cancer diagnostic test, CyPath® Lung, with the number of tests processed increasing steadily each month and more than doubling since the start of 2025. October's test volume increased by 111% over the 2025 monthly average.

"The increase in CyPath® Lung test volume demonstrates that physicians are increasingly recognizing the clinical value of CyPath® Lung in detecting lung cancer at its earliest and most treatable stages," said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. "This steady adoption of our test underscores the success of our outreach to pulmonologists, health systems, and VA medical centers, as well as the growing trust among clinicians who are incorporating CyPath® Lung into the diagnostic pathway for patients with indeterminate pulmonary nodules discovered incidentally or through recommended annual screening for lung cancer."

In the first 10 months of 2025, sales of CyPath® Lung saw consistent month-over-month and quarter-over-quarter growth. Tests processed in October 2025 continue the upward trend with completed tests representing a 111% increase over the monthly average for the first nine months of 2025. Third-quarter sales volume increased 95% over the prior quarter. Medical practices with multiple CyPath® Lung orders increased 106% in the third-quarter compared to the prior quarter and increased by 67% in October compared to the 2025 year-to-date monthly average.

"We're proud of the progress made this year and expect the upward trend in sales volume to continue. Each new physician adopting CyPath® Lung brings us closer to changing the standard of care in early lung cancer detection," Ms. Zannes said.